PA
RARE icon

Pinnacle Associates’s Ultragenyx Pharmaceutical RARE Stock Holding History

Pinnacle Associates’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.15M Sell
102,710
-8,850
-8% -$199K 0.03% 383
2025
Q4 		$2.57M Sell
111,560
-3,285
-3% -$108K 0.03% 356
2025
Q3 		$3.45M Buy
114,845
+577
+0.5% +$17.3K 0.05% 304
2025
Q2 		$4.15M Sell
114,268
-29,107
-20% -$1.05M 0.06% 265
2025
Q1 		$5.19M Sell
143,375
-5,118
-3% -$213K 0.08% 233
2024
Q4 		$6.25M Buy
148,493
+29,133
+24% +$1.45M 0.08% 211
2024
Q3 		$5.71M Sell
119,360
-41,660
-26% -$2.12M 0.1% 222
2024
Q2 		$6.62M Buy
161,020
+41,633
+35% +$1.78M 0.1% 202
2024
Q1 		$5.57M Buy
119,387
+27
+0% +$1.27K 0.09% 234
2023
Q4 		$5.71M Buy
119,360
+5
+0% +$194 0.1% 225
2023
Q3 		$4.26M Sell
119,355
-3,841
-3% -$152K 0.08% 244
2023
Q2 		$5.68M Sell
123,196
-3,201
-3% -$148K 0.1% 217
2023
Q1 		$5.07M Sell
126,397
-2,039
-2% -$87.5K 0.1% 205
2022
Q4 		$5.95M Sell
128,436
-1,982
-2% -$78K 0.13% 183
2022
Q3 		$5.4M Sell
130,418
-3,640
-3% -$187K 0.12% 193
2022
Q2 		$8M Sell
134,058
-2,221
-2% -$137K 0.17% 147
2022
Q1 		$9.9M Sell
136,279
-5,295
-4% -$368K 0.18% 150
2021
Q4 		$11.9M Sell
141,574
-782
-0.5% -$63.6K 0.21% 132
2021
Q3 		$12.8M Sell
142,356
-4,159
-3% -$376K 0.24% 119
2021
Q2 		$14M Buy
146,515
+1,225
+0.8% +$128K 0.25% 115
2021
Q1 		$16.5M Sell
145,290
-13,065
-8% -$1.78M 0.32% 92
2020
Q4 		$21.9M Sell
158,355
-9,331
-6% -$1.11M 0.45% 66
2020
Q3 		$13.8M Sell
167,686
-6,513
-4% -$540K 0.33% 85
2020
Q2 		$13.6M Sell
174,199
-4,572
-3% -$303K 0.34% 85
2020
Q1 		$7.94M Sell
178,771
-33,616
-16% -$1.75M 0.24% 116
2019
Q4 		$9.07M Buy
212,387
+139,380
+191% +$5.75M 0.2% 137
2019
Q3 		$3.12M Buy
+73,007
New +$3.97M 0.07% 249

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Pinnacle Associates's RARE Position: Q1 2026 in Review

Pinnacle Associates reduced its Ultragenyx Pharmaceutical (RARE) stake by 7.9% in Q1 2026, selling an estimated $199K and leaving 102,710 shares worth $2.15M. The position accounts for 0.03% of the portfolio, ranked #383.

Pinnacle Associates first reported a position in RARE in Q3 2019 and has held it in 27 quarters since. The position peaked at $21.9M in Q4 2020. 296 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Pinnacle Associates held 102,710 shares of Ultragenyx Pharmaceutical worth $2.15M as of Q1 2026.
  • Pinnacle Associates sold 8,850 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $199K.
  • Ultragenyx Pharmaceutical made up 0.03% of Pinnacle Associates's portfolio in Q1 2026, its #383 holding.
  • Pinnacle Associates first reported a position in Ultragenyx Pharmaceutical in Q3 2019 and has held it in 27 quarters since.
  • Pinnacle Associates's Ultragenyx Pharmaceutical position peaked at $21.9M in Q4 2020.
  • 296 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Pinnacle Associates's 13F filing for Q1 2026, filed 22 Apr 2026.